2025 Poster Presentations
P01: Rapid and Reproducible TAb/NAb AAV Assays Across Serotypes and Species to support Global Preclinical Programs, Presented by Quentin O., Altasciences
P02: A Systematic Approach for Improving the Drug Tolerance of an ADA Assay for a Peptide Therapeutic, Presented by Adam Z., Apellis Pharmaceuticals, Inc.
P03: A Novel Neutralizing Antibody Assay for Detection of ß-NGF Arm-Specific Antibodies Against a ß-NGF/TNFR2 Bispecific Therapeutic Antibody, Presented by Nellie M., AstraZeneca
P04: Overcoming Target Interference in Canine Plasma During Development of an ADA Assay to Support a Biotherapeutic for Treatment of Canine Chronic Kidney Disease, Presented by Lisa D., BioAgilytix
P05: Development of Cross-Reactivity ADA Assays for Peptide and Cytokine Drugs, Presented by Fangfang C., Boehringer Ingelheim Pharmaceuticals
P06: Targeted Immunogenicity Characterization to Maximize Patient Value in Multispecific Therapeutics, Presented by Elisa O., Boehringer Ingelheim Pharmaceuticals
P07: Mitigating Target Interference Challenges During Immunogenicity Assay Method Development, Presented by Kavitha A., Bristol Myers Squibb
P08: Antibody Conjugation Procedure Optimization for Large Scale Production to Support ADA Detection in ECL Assay Method, Presented by Bhagyshri C. & Atiya T., Gilead Sciences, Inc.
P09: A Mass Spectrometry Platform for Characterising the Human Immune Response to Improve Targeted Therapies, Presented by Peter A., IMC Krems University of Applied Sciences
P10: Linking In Vitro MAPPs Results to Clinical Immunogenicity, Presented by Elise P., ImmuneSpec
P11: Development and Validation of a Neutralizing Antibody (NAb) Assay to Support Bi-Specific Biologics Therapeutics in AlphsLISA Platform, Presented by Shixue S., Johnson & Johnson Innovative Medicine
P12: Leveraging AI/ML to Predict Anti-Idiotype Binning for Ligand Binding Assays, Presented by Pooja K., Merck & Co., Inc.
P13: In Vitro Characterization of Solrikitug, a Differentiated Anti-TSLP Antibody, Provides Distinct Epitope Binding Profile and Superior Potency Compared to Tezepelumab, Presented by Mlana L. & Rhea H., Mosaic Biosciences, Inc.
P14: Identification of Immunomodulatory Compounds by High-Throughput Proteomics: Insights from Quantification of 1000 Proteins in a 20,000 Sample Screen, Presented by Amy J., Nomic Bio
P15: Validation of Anti-ADC Assays with ADA Characterization to Support Micvotabart Pelidotin Clinical Studies, Presented by Diana A., Pyxis Oncology
P16: Human-Based In Vitro MIMIC Model Enables Prediction of mRNA Vaccine Immunogenicity, Presented by Ranjitha U., Sanofi
P17: Overcoming Matrix Interference in High Drug Tolerant ADA Assays Across Species for an Engineered IgG1 Fc Fragment, Presented by Ivan I., Smithers
P18: Unveiling Sex Bias in AAV Vector Responses: From Pre-Existing Antibodies to Innate Immunogenicity, Presented by Leila, U.S. Food and Drug Administration